These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26587311)

  • 1. Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.
    Fuchs JD; Bart PA; Frahm N; Morgan C; Gilbert PB; Kochar N; DeRosa SC; Tomaras GD; Wagner TM; Baden LR; Koblin BA; Rouphael NG; Kalams SA; Keefer MC; Goepfert PA; Sobieszczyk ME; Mayer KH; Swann E; Liao HX; Haynes BF; Graham BS; McElrath MJ;
    J AIDS Clin Res; 2015 May; 6(5):. PubMed ID: 26587311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
    Crank MC; Wilson EM; Novik L; Enama ME; Hendel CS; Gu W; Nason MC; Bailer RT; Nabel GJ; McDermott AB; Mascola JR; Koup RA; Ledgerwood JE; Graham BS;
    PLoS One; 2016; 11(11):e0166393. PubMed ID: 27846256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
    Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH
    J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.
    Ophorst OJ; Radosević K; Havenga MJ; Pau MG; Holterman L; Berkhout B; Goudsmit J; Tsuji M
    Infect Immun; 2006 Jan; 74(1):313-20. PubMed ID: 16368986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.
    Bart PA; Huang Y; Karuna ST; Chappuis S; Gaillard J; Kochar N; Shen X; Allen MA; Ding S; Hural J; Liao HX; Haynes BF; Graham BS; Gilbert PB; McElrath MJ; Montefiori DC; Tomaras GD; Pantaleo G; Frahm N
    J Clin Invest; 2014 Nov; 124(11):4843-56. PubMed ID: 25271627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
    Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
    PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
    Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
    J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.
    Thorner AR; Lemckert AA; Goudsmit J; Lynch DM; Ewald BA; Denholtz M; Havenga MJ; Barouch DH
    J Virol; 2006 Dec; 80(24):12009-16. PubMed ID: 17035318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.
    Nanda A; Lynch DM; Goudsmit J; Lemckert AA; Ewald BA; Sumida SM; Truitt DM; Abbink P; Kishko MG; Gorgone DA; Lifton MA; Shen L; Carville A; Mansfield KG; Havenga MJ; Barouch DH
    J Virol; 2005 Nov; 79(22):14161-8. PubMed ID: 16254351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses.
    Loré K; Adams WC; Havenga MJ; Precopio ML; Holterman L; Goudsmit J; Koup RA
    J Immunol; 2007 Aug; 179(3):1721-9. PubMed ID: 17641038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial.
    Zhu F; Jin P; Zhu T; Wang W; Ye H; Pan H; Hou L; Li J; Wang X; Wu S; Wang Y; Gou J; Huang H; Wu H; Wang X; Chen W
    Clin Infect Dis; 2022 Aug; 75(1):e783-e791. PubMed ID: 34551104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
    Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
    PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.
    Baden LR; Karita E; Mutua G; Bekker LG; Gray G; Page-Shipp L; Walsh SR; Nyombayire J; Anzala O; Roux S; Laher F; Innes C; Seaman MS; Cohen YZ; Peter L; Frahm N; McElrath MJ; Hayes P; Swann E; Grunenberg N; Grazia-Pau M; Weijtens M; Sadoff J; Dally L; Lombardo A; Gilmour J; Cox J; Dolin R; Fast P; Barouch DH; Laufer DS;
    Ann Intern Med; 2016 Mar; 164(5):313-22. PubMed ID: 26833336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.
    Koblin BA; Casapia M; Morgan C; Qin L; Wang ZM; Defawe OD; Baden L; Goepfert P; Tomaras GD; Montefiori DC; McElrath MJ; Saavedra L; Lau CY; Graham BS;
    PLoS One; 2011; 6(9):e24517. PubMed ID: 21931737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.
    Cheng C; Gall JG; Nason M; King CR; Koup RA; Roederer M; McElrath MJ; Morgan CA; Churchyard G; Baden LR; Duerr AC; Keefer MC; Graham BS; Nabel GJ
    J Virol; 2010 Jan; 84(1):630-8. PubMed ID: 19846512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.
    Walsh SR; Moodie Z; Fiore-Gartland AJ; Morgan C; Wilck MB; Hammer SM; Buchbinder SP; Kalams SA; Goepfert PA; Mulligan MJ; Keefer MC; Baden LR; Swann EM; Grant S; Ahmed H; Li F; Hertz T; Self SG; Friedrich D; Frahm N; Liao HX; Montefiori DC; Tomaras GD; McElrath MJ; Hural J; Graham BS; Jin X;
    J Infect Dis; 2016 Feb; 213(4):541-50. PubMed ID: 26475930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.
    Sarwar UN; Novik L; Enama ME; Plummer SA; Koup RA; Nason MC; Bailer RT; McDermott AB; Roederer M; Mascola JR; Ledgerwood JE; Graham BS;
    PLoS One; 2014; 9(9):e106240. PubMed ID: 25264782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.
    Sumida SM; Truitt DM; Kishko MG; Arthur JC; Jackson SS; Gorgone DA; Lifton MA; Koudstaal W; Pau MG; Kostense S; Havenga MJ; Goudsmit J; Letvin NL; Barouch DH
    J Virol; 2004 Mar; 78(6):2666-73. PubMed ID: 14990686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
    Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
    Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.